Ross Merkin, MD

Articles by Ross Merkin, MD

Patient and Disease Factors Guide First-Line Selection

ByKevin Harrington, MD, PhD, FRCP, FRCR, FRSB,Will Ince, MRCP, FRCR,Ross Merkin, MD

November 6th 2026

Ross Merkin, MD, explains that the goal of first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma is to help the patient, which usually means treating the cancer.

Immunotherapy Reshapes First-Line Recurrent Head and Neck Cancer

ByKevin Harrington, MD, PhD, FRCP, FRCR, FRSB,Will Ince, MRCP, FRCR,Ross Merkin, MD

November 6th 2026

Kevin Harrington, MBBS, PhD, FRCP, FRCR, opens a discussion on how checkpoint inhibitors changed first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.

HPV Status and Curative-Intent Future Directions

ByKevin Harrington, MD, PhD, FRCP, FRCR, FRSB,Will Ince, MRCP, FRCR,Ross Merkin, MD

January 5th 2026

Closing reflections on recurrent or metastatic head and neck squamous cell carcinoma center on human papillomavirus (HPV) status and curative-intent strategies.

Preparing Practices and Treatment at Progression

ByKevin Harrington, MD, PhD, FRCP, FRCR, FRSB,Will Ince, MRCP, FRCR,Ross Merkin, MD

January 5th 2026

Will Ince, MRCP, FRCR, advises community oncologists to prepare for patients with recurrent or metastatic head and neck squamous cell carcinoma to live longer, which will increase clinic volume and affect service organization.